Ocugen (OCGN) Share-based Compensation (2014 - 2026)
Ocugen (OCGN) posted Share-based Compensation of $3.4 million for Q1 2026, up 358.21% on a QoQ basis from -$1.3 million in Q4 2025, and up 80.27% year-over-year from $1.9 million in Q1 2025.
Ocugen (OCGN) Share-based Compensation (2014 - 2026) Analysis & Trends
Ocugen's Share-based Compensation history runs 13 years deep, the most recent figure standing at $3.4 million for Q1 2026.
- Quarterly Share-based Compensation rose 80.27% year-over-year to $3.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.2 million (down 21.45% YoY) and the FY2024 annual result came in at $1.0 million, down 89.15% from the prior year.
- Share-based Compensation was $3.4 million for Q1 2026 at Ocugen, up from -$1.3 million in the prior quarter.
- Across five years, Share-based Compensation topped out at $3.4 million in Q1 2026 and bottomed at -$1.3 million in Q4 2025.
- A 5-year average of $2.0 million and a median of $2.0 million in 2025 frame the typical range for Share-based Compensation.
- Annual changes were most pronounced in 2022 — Share-based Compensation surged 296.04% — and 2025, when it plunged 246.71%.
- Ocugen's Share-based Compensation stood at $2.7 million in 2022, then tumbled by 35.46% to $1.7 million in 2023, then tumbled by 47.91% to $897000.0 in 2024, then plunged by 246.71% to -$1.3 million in 2025, then surged by 358.21% to $3.4 million in 2026.
- Business Quant data shows OCGN's Share-based Compensation at $3.4 million in Q1 2026, -$1.3 million in Q4 2025, and $2.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 6.39 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 9.26 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 1.18 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 166.40 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 257.40 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 87.30 Mn |
| 10 | Ocugen | 63.79 Mn | 63.79 Mn | - | 3.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.40 Mn |
| Mar 31, 2026 | 3.40 Mn |
| Dec 31, 2025 | -1.32 Mn |
| Dec 31, 2025 | -1.32 Mn |
| Sep 30, 2025 | 1.98 Mn |
| Sep 30, 2025 | 1.98 Mn |
| Jun 30, 2025 | 1.10 Mn |
| Jun 30, 2025 | 1.10 Mn |
| Mar 31, 2025 | 1.89 Mn |
| Mar 31, 2025 | 1.89 Mn |
| Dec 31, 2024 | 897,000.00 |
| Dec 31, 2024 | 897,000.00 |
| Sep 30, 2024 | 1.89 Mn |
| Sep 30, 2024 | 1.89 Mn |
| Jun 30, 2024 | 1.90 Mn |
| Jun 30, 2024 | 1.90 Mn |
| Mar 31, 2024 | 1.76 Mn |
| Mar 31, 2024 | 1.76 Mn |
| Dec 31, 2023 | 1.72 Mn |
| Dec 31, 2023 | 1.72 Mn |